Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: Current therapeutic concepts

Pharmacotherapy

Volumn 29, Issue 11, 2009, Pages 1306-1325

  McCoy, Dorothy ^a,b   DePestel, Daryl D ^c   Carver, Peggy L ^c  

^a RUTGERS UNIVERSITY   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Amphotericin B; Antifungals; Azoles; Echinocandins; Hematopoietic stem cell transplant; HSCT; IFI; Immunosuppression; Invasive fungal infection; Prophylaxis

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; ANIDULAFUNGIN; BASILIXIMAB; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID DERIVATIVE; DACLIZUMAB; ETANERCEPT; FLUCONAZOLE; FLUDARABINE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAPAMYCIN; RITUXIMAB; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; VORICONAZOLE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BIOPSY TECHNIQUE; CANDIDA; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG ERUPTION; DRUG FORMULATION; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGUS CULTURE; GENETIC POLYMORPHISM; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INVASIVE MYCOSIS; MIXED INFECTION; MORTALITY; MYCOSIS; NEPHROTOXICITY; PATHOGENESIS; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; VISUAL DISORDER;

ADULT; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 70350514229     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.11.1306     Document Type: Review

References (71)

1. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007;78:275-282 (Pubitemid 46365078)
2. Ellis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13:3-11. (Pubitemid 24060882)
3. Philpott-Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993;31:973-984 (Pubitemid 23218159)
4. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant Infect Dis 2002;4:3-9. (Pubitemid 34786819)
5. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991;164:731-740
6. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100: 4358-4366 (Pubitemid 35429674)
7. Jantunen E, Nihtinen A, Anttila VJ. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transpl Infect Dis 2008;10:156-161 (Pubitemid 351704011)
8. Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766-1777
9. Jantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004;73:174-178 (Pubitemid 39062240)
10. Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-482 (Pubitemid 34155525)
11. Munoz P, Guinea J, Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006;12(suppl 7):24-39. (Pubitemid 44756308)
12. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43(supp 1):S49-58. (Pubitemid 41038548)
13. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):16.
14. Plantinga TS, van der Velden WJ, Ferwerda B, et al. Early stop polymorphism in human DECTIN-1 is associated with increased Candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009;49:724-732
15. Strasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-468 (Pubitemid 43905467)
16. Alexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005;80:868-871
17. Girmenia C, Moleti ML, Micozzi A, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005;43:5395-5396
18. Pavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005;43:4902-4904
19. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39:743-746 (Pubitemid 39180450)
20. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360
21. Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004;39:588-590
22. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950-952 (Pubitemid 38252550)
23. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004;39:584-587 (Pubitemid 39120940)
24. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005;40:e35-7.
25. Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol 2005;84:40-47
26. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-1324 (Pubitemid 32405904)
27. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917 (Pubitemid 34229758)
28. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-1821.
29. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
30. Hashiguchi K, Niki Y, Soejima R. Cyclophosphamide induces false-positive results in detection of Aspergillus antigen in urine. Chest 1994;105:975-976
31. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004;38:917-920
32. Dodds Ashley E, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006;43:S28-39.
33. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-1744
34. Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008;61:17-25.
35. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-211 (Pubitemid 351269158)
36. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138:705-713
37. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103: 1527-1533 (Pubitemid 38168674)
38. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50: 1570-1572
39. Trifilio A, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-456 (Pubitemid 47288224)
40. Imhof A, Schaer DJ, Schwarz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006;136:739-742 (Pubitemid 46032197)
41. Brüggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008;30: 403-411
42. Surowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008;28:719-729 (Pubitemid 351975376)
43. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-172
44. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-1636 (Pubitemid 350234311)
45. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:127-134
46. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416 (Pubitemid 39518200)
47. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552
48. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851
49. Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, for the Canadian Fluconazole Prophylaxis Study Group. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999;28:331-340 (Pubitemid 29241223)
50. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial: GIMEMA infection program, gruppo Italiano malattie ematologiche dell' adulto. Clin Infect Dis 1999;28:250-255
51. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American marrow transplant group. Bone Marrow Transplant 2000;25:853-859 (Pubitemid 30209678)
52. MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002;112:369-379
53. Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999;23: 163-168 (Pubitemid 29048218)
54. Penack O, Reinwald M, Schmidt-Hieber M, et al. Low dose liposomal amphotericin B as prophylaxis of invasive fungal infections in patients with prolonged neutropenia: results from a phase III trial [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:M-975.
55. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole versus fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347 (Pubitemid 46148776)
56. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002;71:260-267 (Pubitemid 35396942)
57. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW, for the U.K. Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999;105:901-911
58. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999;93: 3654-3661 (Pubitemid 29249811)
59. Tollemar J, Ringden O, Anderson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25:1495-1497 (Pubitemid 23079075)
60. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-897
61. Egger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: a prospective, randomized, single-center study. Support Care Cancer 1995;3:139-146
62. Huijgens PC, Simoons-Smit AM, van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in hemato-oncology. J Clin Pathol 1999;52:376-380
63. Nucci M, Biasoli I, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000;30:300-305 (Pubitemid 30131537)
64. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-514 (Pubitemid 24370881)
65. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients [abstract]. Blood 2007;110:abstract 163. Available from http://abstracts.hematologylibrary.org/cgi/content/ abstract/ashmtg;110/11/163? maxtoshow=&HITS=10&hits=10&RES ULTFORMAT=&fulltext= voriconazole&searchid=1&FIRSTINDEX= 0&volume=110&issue= 11&resourcetype=HWCIT&eaf. Accessed October 2, 2008.
66. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408 (Pubitemid 351589940)
67. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-2061 (Pubitemid 30696231)
68. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103: 1557-1559 (Pubitemid 38168678)
69. Marks DI, Kibbler C, Pagliuca A, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract]. In: Program and abstracts of the 49th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2009:M-1249a.
70. ClinicalTrials.gov. Identifier NCT00079222. Randomized trial of safety and tolerability of intravenous/oral voriconazole versus intravenous/oral itraconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Available from http://www.clinicaltrials.gov/ ct2/results?term=voriconazole. Accessed December 18, 2007.
71. O'Sullivan AK, Weinstein MC, Pandya A, et al. Cost-effectiveness of posaconazole vs fluconazole in the prevention of invasive fungal infections among patients with graft-versus-host disease (GVHD) in the U.S. [abstract] Blood 2007;110: abstract 3336. Available from http://abstracts.hematology library.org/cgi/content/abstract/110/11/3336?maxtoshow=&HIT S=10&hits=10&RESULTFORMAT=&fulltext=posaconazole&se archid=1&FIRSTINDEX=0&volume=110&issue=11&resourcet ype=HWCIT. Accessed October 2, 2008.